Table 1.

Active clinical trials using HDACi in combination with other agents

HDACiSynonymPhaseCombination drug(s)Indication
VorinostatSAHAIAzacitidineNasopharyngeal carcinoma, lymphoma
IDecitabineAdvanced solid tumors, lymphoma, leukemia
IDecitabineHematologic cancer or other diseases
IDecitabineMyelodysplastic syndromes, AML
IBortezomibLung cancer
IBortezomibMetastatic solid tumors
IBortezomibAdvanced lung cancer
IBortezomibAdvanced multiple myeloma
INPI-0052Lung cancer, pancreatic cancer, melanoma, lymphoma
I/IIAzacitidineMyelodysplastic syndromes, AML
IIBortezomibRecurrent glioblastoma multiforme
IIBortezomibRecurrent lymphoma
IIBortezomibRefractory multiple myeloma
IIIBortezomibMultiple myeloma
EntinostatMS-275IAzacitidineLeukemia; myelodysplastic syndromes
I/IIAzacitidineLung cancer
IIAzacitidineLeukemia; myelodysplastic syndromes
PanobinostatLBH589IBortezomibMultiple myeloma
I/IIDecitabineMyelodysplastic syndromes, AML
Valproic acidValproateIAzacitidineAdvanced cancers
IDecitabineLeukemia; lymphoma
IDecitabineLymphoma
IDecitabineLung cancer
IIDecitabineMyelodysplastic syndromes; leukemia
I/IIAzacitidine; ATRAMyelodysplastic syndromes; leukemia
IIAzacitidine; ATRAMyelodysplastic syndromes
IIAzacitidine; ATRAMyelodysplastic syndromes; leukemia
RomidepsinDepsipeptideI/IIBortezomibMultiple myeloma
IIBortezomibMultiple myeloma
BelinostatPXD101IAzacitidineLeukemia; myelodysplastic syndromes
IBortezomibAdvanced solid tumors, lymphomas
MGCD0103IIAzacitidineMyelodysplastic syndrome; AML